Literature DB >> 20483155

Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007).

Mette Nørgaard1, Annette Østergaard Jensen, Jacob Bonde Jacobsen, Kara Cetin, Jon P Fryzek, Henrik Toft Sørensen.   

Abstract

PURPOSE: We describe mortality in patients with prostate cancer with and without bone metastasis further characterized by skeletal related events.
MATERIALS AND METHODS: We performed a cohort study of 23,087 incident patients with prostate cancer with a median 2.2-year followup identified through the Danish National Patient Registry from 1999 to 2007. We estimated the cumulative incidence of bone metastasis and skeletal related events, and described survival using the Kaplan-Meier method. Based on a Cox proportional hazard model we estimated mortality rate ratios and associated 95% CIs comparing mortality rates between patients by bone metastasis with and without skeletal related events, adjusting for age and comorbidity.
RESULTS: Of the patients 569 (almost 3%) presented with bone metastasis at prostate cancer diagnosis, of whom 248 (43.6%) experienced a skeletal related event during followup. Of the 22,404 men (97% overall) without bone metastasis at diagnosis 2,578 (11.5%) were diagnosed with bone metastasis and 1,329 (5.9%) also experienced a skeletal related event during followup. One and 5-year survival was 87% and 56% in patients with prostate cancer without bone metastasis, 47% and 3% in those with bone metastasis, and 40% and less than 1% in those with bone metastasis and skeletal related events, respectively. Compared with men with prostate cancer without bone metastasis the adjusted 1-year mortality rate ratio was 4.7 (95% CI 4.3-5.2) in those with bone metastasis and no skeletal related events, and 6.6 (95% CI 5.9-7.5) in those with bone metastasis and a skeletal related event.
CONCLUSIONS: Bone metastasis and skeletal related events predict poor prognosis in men with prostate cancer. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20483155     DOI: 10.1016/j.juro.2010.03.034

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  148 in total

1.  Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer.

Authors:  Moritz Binder; Irene M Shui; Kathryn M Wilson; Kathryn L Penney; Lorelei A Mucci; Adam S Kibel
Journal:  Cancer Causes Control       Date:  2015-09-25       Impact factor: 2.506

2.  Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine.

Authors:  Joseph W Kim; Ravi A Madan; James L Gulley
Journal:  Clin Genitourin Cancer       Date:  2011-10-21       Impact factor: 2.872

Review 3.  Fracture risk assessment and clinical decision making for patients with metastatic bone disease.

Authors:  Timothy A Damron; Kenneth A Mann
Journal:  J Orthop Res       Date:  2020-03-23       Impact factor: 3.494

Review 4.  Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?

Authors:  Simon P Gampenrieder; Gabriel Rinnerthaler; Richard Greil
Journal:  Breast Care (Basel)       Date:  2014-10       Impact factor: 2.860

5.  Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Transl Androl Urol       Date:  2019-07

Review 6.  MicroRNAs in prostate cancer: From function to biomarker discovery.

Authors:  Ahmed A Moustafa; Hogyoung Kim; Rasha S Albeltagy; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2018-06

7.  The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.

Authors:  J Jayasekera; E Onukwugha; K Bikov; C D Mullins; B Seal; A Hussain
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

8.  Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.

Authors:  Matthew R Smith; Fred Saad; Stephane Oudard; Neal Shore; Karim Fizazi; Paul Sieber; Bertrand Tombal; Ronaldo Damiao; Gavin Marx; Kurt Miller; Peter Van Veldhuizen; Juan Morote; Zhishen Ye; Roger Dansey; Carsten Goessl
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

Review 9.  Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.

Authors:  Laura Evangelista; Francesco Bertoldo; Francesco Boccardo; Giario Conti; Ilario Menchi; Francesco Mungai; Umberto Ricardi; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-09       Impact factor: 9.236

10.  Evaluation of Posttreatment Follow-Up of Patients With Prostate Cancer Relative to the American College of Radiology's Appropriateness Criteria.

Authors:  Jennifer S McDonald; Rickey E Carter; R Jeffrey Karnes; John D Port; Akira Kawashima; Stephanie K Carlson; Claire E Bender
Journal:  AJR Am J Roentgenol       Date:  2015-11       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.